Financial Performance - The company's operating revenue for Q1 2025 was CNY 129,071,756.14, representing a 3.33% increase compared to CNY 124,911,943.02 in the same period last year[3] - Net profit attributable to shareholders was CNY 59,842,662.17, reflecting a 14.63% increase from CNY 52,202,813.76 year-over-year[3] - Total operating revenue for Q1 2025 was CNY 129,071,756.14, an increase of 1.85% compared to CNY 124,911,943.02 in Q1 2024[18] - Net profit for Q1 2025 was CNY 59,842,662.17, up 14.93% from CNY 52,202,813.76 in Q1 2024[19] - Basic and diluted earnings per share decreased by 15.91% to CNY 0.37, compared to CNY 0.44 in the same period last year[3] - Earnings per share (EPS) for Q1 2025 was CNY 0.37, down from CNY 0.44 in Q1 2024[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 4.00% to CNY 53,217,171.28, down from CNY 55,435,440.02 in the previous year[3] - Cash flow from operating activities for Q1 2025 was CNY 53,217,171.28, a decrease from CNY 55,435,440.02 in Q1 2024[23] - Cash inflow from investment activities was CNY 65,441,013.89, significantly higher than CNY 3,000,000.00 in Q1 2024[24] - Cash flow from financing activities generated a net inflow of CNY 3,721,723.19 compared to a net outflow of CNY 1,755,469.56 in Q1 2024[24] - The net increase in cash and cash equivalents for the period is 94,329,440.61, compared to 45,190,347.54 in the previous period[25] - The beginning balance of cash and cash equivalents is 282,535,421.74, remaining unchanged from the previous period[25] - The ending balance of cash and cash equivalents is 376,864,862.35, an increase from 327,725,769.28 in the previous period[25] Assets and Liabilities - Total assets increased by 2.26% to CNY 1,434,081,842.95, up from CNY 1,402,448,475.00 at the end of the previous year[4] - As of March 31, 2025, the company's total assets amounted to RMB 1,434,081,842.95, an increase from RMB 1,402,448,475.00 as of December 31, 2024, reflecting a growth of approximately 2.3%[12] - The company's current assets totaled RMB 1,062,599,399.00, compared to RMB 1,031,934,369.91 at the end of 2024, indicating an increase of about 2.9%[14] - The company's total liabilities decreased to RMB 139,910,551.94 from RMB 168,213,793.02, a reduction of approximately 16.8%[15] - The total equity increased to RMB 160,559,967.00 from RMB 160,000,000.00, reflecting a growth of about 0.35%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,072[8] - The largest shareholder, Yunjia Far East Co., Ltd., holds 58.80% of the shares, totaling 94,080,000 shares[8] - Shareholders' equity attributable to shareholders rose by 4.86% to CNY 1,294,171,291.01, compared to CNY 1,234,234,681.98 at the end of the previous year[4] Operational Insights - The company received government subsidies amounting to CNY 80,944.59, which are closely related to its normal business operations[5] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[10] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported[10] Cost Management - Total operating costs decreased to CNY 59,389,758.13 from CNY 64,012,373.77, representing a reduction of 7.88%[18] - Research and development expenses for Q1 2025 were CNY 2,270,871.64, down from CNY 3,845,805.32 in Q1 2024, indicating a 40.83% reduction[18] - The company reported a financial expense of CNY -1,777,303.27, which is an increase in costs compared to CNY -951,684.20 in the previous year[19] Inventory and Receivables - Accounts receivable rose to RMB 94,314,926.51 from RMB 87,850,912.95, marking an increase of around 7.3%[12] - Inventory decreased slightly to RMB 43,655,134.17 from RMB 45,205,028.30, a decline of approximately 3.4%[14] - The company reported a significant reduction in other payables from RMB 123,181,401.33 to RMB 94,577,217.84, a decrease of about 23.2%[15]
小方制药(603207) - 2025 Q1 - 季度财报